MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Closed 06-11 16:00:00 EDT

3.92

-0.04

-1.01%

盘后3.93

+0.01+0.21%

19:48 EDT

High4.06	Low3.59	Vol426.03K
Open3.85	D1 Closing3.96	Amplitude11.87%
Mkt Cap85.60M	Tradable Cap68.23M	Total Shares21.84M
T/O1.63M	T/O Rate2.45%	Tradable Shares17.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":3.92,"timestamp":1718136000000,"preClose":3.96,"halted":0,"volume":426029,"hourTrading":{"tag":"盘后","latestPrice":3.9281,"preClose":3.92,"latestTime":"19:48 EDT","volume":653,"amount":2548.0159,"timestamp":1718149730803},"delay":0,"floatShares":17406300,"shares":21837149,"eps":-1.590295,"marketStatus":"Closed","change":-0.04,"latestTime":"06-11 16:00:00 EDT","open":3.85,"high":4.06,"low":3.59,"amount":1628152.473126,"amplitude":0.118687,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.590295,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1718179200000},"marketStatusCode":5,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":3.96,"preHourTrading":{"tag":"盘前","latestPrice":3.8897,"preClose":3.96,"latestTime":"09:28 EDT","volume":1468,"amount":5583.1325384,"timestamp":1718112508749},"postHourTrading":{"tag":"盘后","latestPrice":3.9281,"preClose":3.92,"latestTime":"19:48 EDT","volume":653,"amount":2548.0159,"timestamp":1718149730803},"volumeRatio":0.435006},"requestUrl":"/m/hq/s/MAIA/","defaultTab":"news","newsList":[{"id":"2441009959","title":"MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2441009959","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441009959?lang=en_us&edition=fundamental","pubTime":"2024-06-08 01:12","pubTimestamp":1717780320,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy.Shares were up 14% to $3.79 in recent trading.The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp.The FDA approved imetelstat for rare blood cancers originating in bone marrow.\"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers,\" said MAIA Chief Executive Vlad Vitoc. \"We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC.MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate it","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2441096588","title":"MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2441096588","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441096588?lang=en_us&edition=fundamental","pubTime":"2024-06-08 00:31","pubTimestamp":1717777860,"startTime":"0","endTime":"0","summary":"FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment. \"MAIA is one of the earliest pioneers of telomere targeting as a therapeutic strategy, and we share in the enthusiasm for the FDA approval of imetelstat for rare blood cancers originating in bone marrow. We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers, and we are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer ,\" said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. \"Our most recent clinical data shows THIO’s exceptional efficacy in checkpoint inhibitor and chemo-resistant patients in NSCLC. We salute Geron for validating the pathway,\" concluded Dr. Vitoc.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zHGazozkoSJj.UgjMn32Cg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f2f9951f7a4d29bb7e01811187a24566","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zHGazozkoSJj.UgjMn32Cg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f2f9951f7a4d29bb7e01811187a24566"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnologys-telomere-targeting-functionality-163100746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","BK4585","BK4588","L","BK4107","BK4139","MAIA"],"gpt_icon":0},{"id":"2441172488","title":"MAIA Biotechnology Reports Progress in Cancer Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2441172488","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441172488?lang=en_us&edition=fundamental","pubTime":"2024-06-07 03:57","pubTimestamp":1717703879,"startTime":"0","endTime":"0","summary":"An announcement from MAIA Biotechnology, Inc. (MAIA) is now available. MAIA Biotechnology, Inc. has announced significant year-to-date achievements...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-reports-progress-in-cancer-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-reports-progress-in-cancer-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","BK4139","MAIA","LU2065732104.USD"],"gpt_icon":0},{"id":"2441274336","title":"MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2441274336","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441274336?lang=en_us&edition=fundamental","pubTime":"2024-06-06 22:07","pubTimestamp":1717682820,"startTime":"0","endTime":"0","summary":"New science for cancer therapy drives powerful value proposition. Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial. Funding of more than $12M year-to-date, including $7.4 million in Q2’24 so far. Newest data shows THIO’s strong outperformance against standard-of-care treatments in non-small cell lung cancer . THIO’s dual mechanism of action is designed to induce telomeric DNA damage and boost cancer-specific immune responses. The Phase 2 THIO-101 clinical trial evaluates THIO sequenced with an immune checkpoint inhibitor , cemiplimab, in patients with advanced non-small cell lung cancer  who failed two or more standard-of-care therapy regimens prior to THIO dosing. MAIA successfully secured a high value clinical supply agreement for the cemiplimab used throughout the THIO-101 trial.\"THIO works well in all doses and has an excellent safety profile, but 180mg has shown the greatest efficacy and is well tolerated compared to existing therapies. Hence, we select","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XVRbUAZmOUYnq1jWFjdHpQ--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9c9f07b05797ad9a05d502b6072564b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XVRbUAZmOUYnq1jWFjdHpQ--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9c9f07b05797ad9a05d502b6072564b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-date-achievements-140700794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU2065732104.USD","MAIA","PRGS","CPI","BK4139","BK4585","BK4588","BK4107","L","BK4211","LU0053666078.USD","PFS","BK4195"],"gpt_icon":0},{"id":"2441843265","title":"MAIA Biotechnology Highlights Clinical Progress and Investor Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2441843265","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441843265?lang=en_us&edition=fundamental","pubTime":"2024-06-05 05:05","pubTimestamp":1717535121,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) has issued an announcement. MAIA Biotechnology, Inc. recently updated investors with a presentation and summary on ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-clinical-progress-and-investor-insights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-clinical-progress-and-investor-insights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","MAIA","PRGS","LU2065732104.USD","BK4139"],"gpt_icon":0},{"id":"2440909234","title":"Recent Run-Up Provides MAIA Biotechnology With Breathing Room","url":"https://stock-news.laohu8.com/highlight/detail?id=2440909234","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440909234?lang=en_us&edition=fundamental","pubTime":"2024-06-04 22:56","pubTimestamp":1717513017,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. is developing the telomere targeting agent, THIO, for various cancer types including non-small cell lung cancer, or NSCLC.The company presented data from its THIO-101 trial at","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340289472/image_1340289472.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340289472/image_1340289472.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4697349-recent-run-up-provides-maia-biotechnology-with-breathing-room","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","LU0889565916.HKD","LU2023250504.SGD","BK4585","LU2362541273.HKD","LU0882574055.USD","LU2362541513.USD","LU2106854487.HKD","LU0053666078.USD","LU1974910355.USD","REGN","MAIA","LU0114720955.EUR","LU0320765992.SGD","LU2362540622.SGD","TIF","LU0058720904.USD","LU0109394709.USD","LU0289739699.SGD","LU1917777945.USD","BK4588"],"gpt_icon":0},{"id":"2440870672","title":"MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2440870672","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440870672?lang=en_us&edition=fundamental","pubTime":"2024-06-04 20:41","pubTimestamp":1717504860,"startTime":"0","endTime":"0","summary":"THIO’s favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment. CHICAGO, June 04, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced new efficacy data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor  cemiplimab  in patients with advanced non-small cell lung cancer  who failed 2 or more standard-of-care therapy regimens. Updated results show a favorable overall response rate  of 38% and a disease control rate  of 85% from THIO + CPI in third-line treatment. The new data was presented in a poster session at the American Society of Clinical Oncology  2024 Annual Meeting on June 3, 2024.The primary objectives of THIO-101 Phase 2 trial are to examine the safety and tolerability of THIO as an anticancer drug and as an immune system primer, and to examine the clinical efficacy of THIO in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/THhEQgkiG8fbxA.HzbnErw--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9a56aa5830b9346135a489f8df98e0e1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/THhEQgkiG8fbxA.HzbnErw--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9a56aa5830b9346135a489f8df98e0e1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-reveals-clinical-data-124100573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CPI","LU0053666078.USD","BK4585","PFS","BK4588","L","BK4211","BK4107","BK4195","BK4139","MAIA"],"gpt_icon":0},{"id":"2440448948","title":"MAIA Biotechnology Unveils Promising THIO-101 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2440448948","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440448948?lang=en_us&edition=fundamental","pubTime":"2024-06-04 04:57","pubTimestamp":1717448254,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) has shared an update. MAIA Biotechnology, Inc. has announced promising results from its Phase 2 THIO-101 clinical t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-promising-thio-101-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-promising-thio-101-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2437756412","title":"ASTS, ALLO and CMCM are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2437756412","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437756412?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:26","pubTimestamp":1716294364,"startTime":"0","endTime":"0","summary":"Gainers: Biodexa Pharmaceuticals  +61%. Edible Garden  +48%. Meta Materials  +34% Announces Update on Naked Short Selling Investigation.  Mmtec  +24%. Larimar Therapeutics  +20% stock rallies 24% on FDA removal of partial clinical hold  LM Funding America  +15%.  Cheetah Mobile  +14%. Allogene Therapeutics  +12%. BriaCell Therapeutics  +13%. SILO Pharma  +9%. Durect  +12% Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis.  BYND Cannasoft Enterprises  +7%. Mobile health Network Solutions  +7%. AST SpaceMobile  +7%. Earlyworks  +7%. AGBA Group Holding  +7%. MAIA Biotechnology  +5%.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108724-asts-allo-and-cmcm-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4202","BK4089","BK4141","DRRX","LMFA","BK4509","CMCM","BK4189","MNDR","BK4123","BK4007","AGBA","MMAT","BK4505","BK4023","BCTX","BCAN","BK4557","BK4184","SILO","ALLO","ELWS","BDRX","EDBL","ASTS","BK4164","MTC","BK4139","BK4196","MAIA","LRMR"],"gpt_icon":0},{"id":"2436916171","title":"MAIA Biotechnology to Present at the BIO International Convention 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2436916171","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436916171?lang=en_us&edition=fundamental","pubTime":"2024-05-17 20:37","pubTimestamp":1715949420,"startTime":"0","endTime":"0","summary":"CHICAGO, May 17, 2024----MAIA Biotechnology, Inc. , a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the upcoming BIO International Convention taking place June 3-6, 2024, in San Diego, California. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe.MAIA Chairman and CEO Vlad Vitoc, M.D. will deliver a presentation featuring up-to-date findings from the Company’s Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor  cemiplimab  in advanced non-small cell lung cancer . THIO is a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer dru","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vJwCfjuIssh3B5TNPW_VXA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cc3512f6106ad3aeb9525461dd364711","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vJwCfjuIssh3B5TNPW_VXA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cc3512f6106ad3aeb9525461dd364711"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-present-bio-international-123700141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4585","CPI","BK4139","LU0053666078.USD","MAIA","BK4588","BIO","L","BK4121"],"gpt_icon":0},{"id":"2435608587","title":"MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2435608587","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435608587?lang=en_us&edition=fundamental","pubTime":"2024-05-16 20:37","pubTimestamp":1715863020,"startTime":"0","endTime":"0","summary":"Poster to present new efficacy data from Phase 2 THIO-101 trial in non-small cell lung cancer . CHICAGO, May 16, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial named \"A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results\" was accepted for poster presentation at the American Society of Clinical Oncology  2024 Annual Meeting, to take place May 31-June 4, 2024, in Chicago, Illinois. The poster is scheduled for presentation on June 3, 2024, from 1:30pm to 4:30pm CST.MAIA’s abstract will be available online at the ASCO Annual Meeting 2024 website during the week prior to the conference start date, and the poster will be published on maiabiotech.com on the day of the presentation, June 3, 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/daGUy8vy62GFYJ6Vlvrw.A--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58b2f29b7fc35006e8fdb74b37f2fc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/daGUy8vy62GFYJ6Vlvrw.A--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58b2f29b7fc35006e8fdb74b37f2fc9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-abstract-accepted-poster-123700525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4117","BK4139","MAIA","BK4107"],"gpt_icon":0},{"id":"2433537987","title":"MAIA Biotechnology Unveils New Business Overview Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2433537987","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433537987?lang=en_us&edition=fundamental","pubTime":"2024-05-08 05:32","pubTimestamp":1715117550,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) has provided an update. MAIA Biotechnology, Inc. has released a new presentation on its business, now accessible on...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-new-business-overview-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-new-business-overview-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2431734289","title":"NKTR, IMNM and MAIA are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431734289","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431734289?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:42","pubTimestamp":1714480935,"startTime":"0","endTime":"0","summary":"Gainers: Cyclacel Pharmaceuticals Inc (CYCC) +60% FORM 10-K/A | Amended Annual Report.  Auddia Inc (AUUD) +34% Announces Strategic Product Expansion With Cloud Based Artificial Intelligence and Natura","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096200-nktr-imnm-and-maia-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["PYPL","MAIA","CYCC","MRIN","NKTR","NNVC","MLEC","BK4023","LU0198837287.USD","LU0238689110.USD","LU0820561818.USD","BK4212","LU0640476718.USD","TENX","BK7040","LU0417517546.SGD","MMM.AU","BRTX","IE00BFTCPJ56.SGD","BK4524","BK4083","IE00B2B36J28.USD","LU1861220207.SGD","BK4527","WGS","BK4139","AUUD","MMM","NKGN","BK4581","MULN","LU0456855351.SGD","OTLY","BLND","LLY","XFOR","LL","LTRX","LU1861217088.USD","BK7501","LU1064131342.USD","IMNM","LU0320765059.SGD","ADXN","BK4563","BOF","LU1267930730.SGD","BK4588","LU2602419157.SGD","LU0158827948.USD"],"gpt_icon":0},{"id":"2431342338","title":"MAIA biotechnology announces share purchase by director in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431342338","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431342338?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:39","pubTimestamp":1714480753,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  announced that independent director Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA’s common stock as part of recent private placement.The securities sold to the company directors participating in the offering were issued pursuant to the company’s 2021 Equity Incentive Plan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096196-maia-biotechnology-announces-share-purchase-by-director-in-private-placement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2431393815","title":"MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393815","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431393815?lang=en_us&edition=fundamental","pubTime":"2024-04-30 01:04","pubTimestamp":1714410240,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology shares hit their 52-week high Monday after it said that independent director Stan Smith made an individual purchase of 147,000 shares, and warrants for 147,000 shares, as part of the company's recent private placement.The stock is up 12% to $3.30 in recent trading, and hit its 52-week high of $3.48 earlier in the session.On Thursday, the biopharmaceutical company entered into definitive agreements for the purchase and sale of 494,000 shares at $2.034 a share, in a private placement to accredited investors and certain company directors.Each share was offered together with a warrant to buy one share at an exercise price of $2.26 a share. The proceeds from the offering are $1 million, prior to offering expenses payable by the company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2431852189","title":"MAIA Biotechnology announces share purchase by director Stan Smith in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431852189","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431852189?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:50","pubTimestamp":1714395033,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  on Monday announced that independent director Stan Smith made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock as part of the company’s recent private placement of common stock and warrants. On April 23, MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share.  Each share of common stock was offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share. The gross proceeds from the offering are about $1 million. MAIA +5.44% premarket to $3.1. Source: Press Release","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095447-maia-biotechnology-announces-share-purchase-by-director-stan-smith-in-private-placement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2431859080","title":"MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431859080","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431859080?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:08","pubTimestamp":1714392480,"startTime":"0","endTime":"0","summary":"Dr. Smith has participated in every MAIA funding round. On April 23, 2024, MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock was offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share. The gross proceeds from the offering are approximately $1.0 million, prior to offering expenses payable by the Company. The securities sold to the Company directors participating in the offering were issued pursuant to the Company’s 2021 Equity Incentive Plan.MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unkn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hv76trxqniGDVv9JbakSTg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/75604e861ada2416454d29bf94198892","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hv76trxqniGDVv9JbakSTg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/75604e861ada2416454d29bf94198892"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-share-purchase-120800051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2429157192","title":"MAIA Biotechnology announces $1M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2429157192","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429157192?lang=en_us&edition=fundamental","pubTime":"2024-04-23 21:02","pubTimestamp":1713877361,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  on Tuesday said it has entered into agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share.  The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The private placement is expected to close on or about April 25. The gross proceeds from the offering are expected to be approximately $1 million. The company intends to use the net proceeds from the offering for to fund research and development activities. Source: Press Release    More on MAIA Biotechnology  MAIA Biotechnology rises 3% on $2.92M private placement Seeking Alpha’s Quant Rating on MAIA Biotechnology Historical earnings data for MAIA Biotechnology Financial information for MAIA Biotechnology","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4092472-maia-biotechnology-announces-1m-private-placement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2429194339","title":"MAIA Biotechnology Announces $1.00 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2429194339","media":"StreetInsider","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429194339?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:51","pubTimestamp":1713876660,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed . The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company directors participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expected to close on or about April ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23100216","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2425554692","title":"MAIA Biotechnology to Present at Two Investor Conferences in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2425554692","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425554692?lang=en_us&edition=fundamental","pubTime":"2024-04-05 20:01","pubTimestamp":1712318460,"startTime":"0","endTime":"0","summary":"CHICAGO, April 05, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York City; and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference taking place April 17-18, 2024.Early completion of enrollment; topline data expected in second half of 2024; . MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3SzwsnaUtXaqnsy1lKwpA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0e31d067524a87064f00ac7754da3287","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3SzwsnaUtXaqnsy1lKwpA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0e31d067524a87064f00ac7754da3287"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-present-two-investor-120100401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAIA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":-0.2235},{"period":"1month","weight":0.2857},{"period":"3month","weight":2.0229},{"period":"6month","weight":3.7087},{"period":"1year","weight":0.7217},{"period":"ytd","weight":2.3846}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0365},{"period":"6month","weight":0.1385},{"period":"1year","weight":0.246},{"period":"ytd","weight":0.127}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}